SAHMRI is delighted to welcome IDT CMAX to South Australia’s Health and Biomedical Precinct, Adelaide BioMed City.
One of the first trials to be run in CMAX’s new, purpose-built clinical trials facility will be a gene therapy study looking at how peripheral arterial disease is treated.
This collaborative gene therapy study will be overseen by SAHMRI’s Heart Health Theme Leader, Professor Steve Nicholls. It will also involve clinicians from The Queen Elizabeth Hospital and The Royal Adelaide Hospital.
Clinical trials to benefit our community
Professor Nicholls said that he is thrilled to be heading up this project.
“Peripheral arterial disease is a circulatory problem where narrowed arteries reduce blood flow to the limbs,” he explained. “This can lead to really serious health complications, and in some cases, amputation of limbs.”
“The beauty of clinical trials being conducted locally is that the benefits can flow back to the community directly. This means we can deliver improved treatments to patients, faster,” Professor Nicholls said.